The largest database of trusted experimental protocols

621 protocols using pd98059

1

Syk-mediated Signaling Pathway Modulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
OREC were pretreated with the Syk-specific inhibitor R406 (1 μM and 5 μM) (InvivoGen, Toulouse, France) for 30 min, and the two different treatment groups were then stimulated with mannan. Cells stimulated with mannan, but not R406, represented the positive control. Cells treated with R406, but not mannan, represented the negative control, while untreated cells represented the blank control.
Then, the downstream pathways were inhibited using specific inhibitors: SB202190 (20 μM, Sigma) for p38, PD98059 (20 μM, Sigma) for ERK1/2, SP600125 (20 μM, Sigma) for JNK, and PDTC (10 μM, Sigma) for NF-κB. The cells were treated with the inhibitor for 60 min and the four different treatment groups were then stimulated with mannan (SB202190 + mannan, PD98059 + mannan, SP600125 + mannan, PDTC + mannan). Cells treated with only inhibitors (SB202190/PD98059/SP600125/PDTC) represented negative controls. Cells treated with mannan, but not inhibitors, represented the positive control, and untreated cells represented the blank control.
+ Open protocol
+ Expand
2

Apoptosis Regulation by ERK1/2 Inhibition

Check if the same lab product or an alternative is used in the 5 most similar protocols
PLA was bought from Sigma-Aldrich (St. Louis, MO, USA). And PD98059, an inhibitor of ERK1/2, was also taken from Sigma-Aldrich. PD98059 was dissolved in dimethyl sulfoxide which was purchased from Sigma-Aldrich. Fetal bovine serum (FBS) was from Gibco (Australian origin). Anti-ERK1/2 and anti-phospho-ERK1/2 were from ImmunoWay Biotechnology (Plano, TX, USA). Anti-Bax, anti-Bcl-2, and anti-caspase-3 were from Cell Signaling Technology (Danvers, MA, USA). Anti-β-actin was acquired from Zhongshanjinqiao Biotechnology (Beijing, China). Annexin V-FITC Apoptosis Detection Kit with propidium iodide (PI) double staining flow cytometry was purchased from Bestbio Biotechnology Company (Shanghai, China).
+ Open protocol
+ Expand
3

Investigating ERK1/2 Inhibition in HPAECs

Check if the same lab product or an alternative is used in the 5 most similar protocols
HPAECs were treated with either 0.01% v/v dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO, USA; 276855) or the ERK1/2 inhibitor PD98059 (Sigma-Aldrich, St. Louis, MO, USA; P215) at varying concentrations up to 30 µM. The cells were then harvested to determine the effects of PD98059 on ERK1/2 activation, cell proliferation, migration, tubule formation, and expression of cell cycle regulatory proteins.
+ Open protocol
+ Expand
4

Modulation of HO-1-BMSC Response

Check if the same lab product or an alternative is used in the 5 most similar protocols
In these experiments, the PI3K/Akt inhibitor LY294002 or the MEK inhibitor PD98059 (both from Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) were applied at a concentration of 5 µM. The HO-1-BMSCs were pre-incubated with LY294002 or PD98059 for 1 h, and then cultured under the aforementioned AKI-KHS treatment conditions for 3 days. The cell cycle profile, proportion of PCNA+ HO-1-BMSCs and proportion of CK18+ HO-1-BMSCs were detected as already described.
+ Open protocol
+ Expand
5

Pharmacological Modulation of Cell Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols
For pharmacological treatments 1321N1 cells were plated in a 6-well plate at a density of 1 × 105 cells per well and incubated at 37 °C with 5% CO2. Compounds (PD98059: 20 µM, Sigma-Aldrich, P215; U0126: 10 nM, Sigma-Aldrich, U120; dissolved in DMSO) were diluted in medium to the final concentration containing 1% DMSO and added to the cultured cells for 48 h (controls contained 1% DMSO as well).
Similarly, PC12 cells were seeded into collagen coated (0.005%, Hoffmann-La Roche) 24-well plates at a density of 3 × 104 cells per well. After 24 h of incubation, the serum was replaced by serum-reduced medium containing medium-diluted pharmacological compounds (K252a: 300 nM, Sigma-Aldrich, 05288; PD98059: 20 µM, Sigma-Aldrich, P215; U0126: 10 nM, Sigma-Aldrich, U120; Bisindolmaleimide: 6 µM, Merck KGaA, Darmstadt, Germany, 203290; LY294002: 50 µM, Sigma-Aldrich, L9908). Then, 6 h later either recombinant NGF (200 ng/mL, SRP3015, Sigma-Aldrich) or medium conditioned by 1321N1 cells and supplemented with the same concentration of the compounds was added.
+ Open protocol
+ Expand
6

Preparation of BBR and PD98059 Stocks

Check if the same lab product or an alternative is used in the 5 most similar protocols
BBR (Cat# B3251) and PD98059 (Cat# sc-3532) were purchased from Sigma-Aldrich (St. Louis, MO, USA) and Santa Cruz Biotechnology (Dallas, TX, USA). The concentration of stocks are 10 mM in water for BBR and 25 mM in DMSO (Sigma-Aldrich, St. Louis, MO, USA) for PD98059.
+ Open protocol
+ Expand
7

Glucose Metabolism Regulation in Granulosa Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
As IR correlates to glucose intolerance and metabolic disorders [26 (link)], measuring glucose concentrations is important to identify IR. To determine whether the IR models of GC were successfully established, we divided the GCs cultured in 24-well plates into 4 groups. The control group (Con) did not receive any treatment; the Dex group (GD) was treated with Dex (Cisen Pharmaceutical, Jining, China.) (100 μmol/L) for 48 h before harvesting supernatant; the insulin group (GI) was treated with human insulin (Jiangsu Wanbang Biopharmaceuticals, Xuzhou, China) (5 IU) [27 ] for 1 h before harvesting supernatant; the Dex + insulin group (GDI) was treated with Dex (100 μmol/L) for 48 h and insulin (5 IU) was added 1 h prior to the end of the culture. To further investigate the effect of IR either in the absence or presence of inhibition of MAPK signaling pathway on GCs, we divided the GCs cultured in 6-well plates or 24-well plates into 3 groups: Con, GD as described above and the Dex + PD98059 group (GDP) which was treated with Dex (100 μmol/L) for 48 h and PD98059 (Sigma-Aldrich, Steinheim, Germany) at 50 μmol/L was added 4 h before the end of the culture [28 ].
+ Open protocol
+ Expand
8

Osteogenic Induction of Dental Pulp Stem Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
The osteogenic induction medium was composed of DMEM, 10−8 M dexamethasone, 50 mg/ml L-ascorbic acid, 0.005 M KH2PO4, 50 mg/ml gentamycin (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), and 10% FBS. The medium was replaced every 3 days for 3 weeks. The conditions used in the different experimental groups were as follows: Control group, DPSCs cultured in DMEM with 10% FBS; Dx group, DPSCs cultured in the osteogenic induction medium dexamethasone (Dx); Dx-PD98059 group, DPSCs cultured in Dx medium with 10 µM PD98059, an inhibitor of Erk1/2; and Dx-SB203580 group, DPSCs cultured in Dx medium with 10 µM SB203580, an inhibitor of p38. The inhibitors, PD98059 (Merck KGaA) and SB203580 (Merck KGaA), were added to the DMEM medium 2 h prior to the shift to osteogenic induction medium (also including PD98059 and SB203580) for continuous culture.
+ Open protocol
+ Expand
9

Investigating Rat RVEC Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols
Rat RVECs from each group were plated in 6-well plates containing 2 ml of complete DMEM medium at a density of 2×105 cells/well. Following cell culture for 24 h at 37°C, medium was exchanged for fresh complete DMEM supplemented with PD98059 (25 µmol/l; Merck KGaA), U46619 (80 µmol/l; Merck KGaA), PD98059 (25 µmol/l) in combination with carnosine (1%; cat. no. C9625; Sigma-Aldrich; Merck KGaA), and U46619 (80 µmol/l) in combination with carnosine (1%). The control group was treated with equal quantities of deionized solvent (DMSO or ethanol). The expression of PKC, ERK and p-ERK in each group was detected 24 h following treatment.
+ Open protocol
+ Expand
10

Evaluating Monocyte Chemotaxis Mechanisms

Check if the same lab product or an alternative is used in the 5 most similar protocols
Boyden chamber (Neuroprobe) chemotaxis was performed using NL monocytes. We evaluated the effects of stimulation with various concentrations of recombinant human CCL21 or 5% RA SF for 2h. PBS and FMLP (10 nM) served as a − and + control, respectively. CCR7 and CCL21 were neutralized with CCR7 Ab and CCL21 Ab (10 μg/ml; R&D Systems), respectively, for 1h prior to chemotactic stimulation. To determine relevant signaling pathways, monocytes were treated for 1h with 5 μM inhibitors of NF-κB (MG132), ERK (PD98059), p38 (SB203580) or PI3K (LY294002) (Millipore). Subsequently, monocyte chemotaxis in response to 10 ng/ml of CCL21 was evaluated for 2h.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!